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Background: Remote ischemic preconditioning (RIPC) protects the heart from ischemia and reperfusion (I/R) injury.
The underlying molecular mechanisms are unclear. It has been demonstrated that Connexin 43 (Cx43) is critically
involved in cardioprotective interventions including classical ischemic preconditioning. In the present study we
investigated the influence of RIPC on the expression patterns of Cx43 after I/R in the rat heart in vivo.
Methods: Male Wistar rats were subjected to 35 min regional myocardial ischemia followed by 2 h reperfusion
with or without 4 cycles of 5 minutes bilateral hind limb ischemia and reperfusion (RIPC), to RIPC without ischemia
or underwent no intervention (Sham). Infarct size was measured by TTC staining. The myocardium was divided into
area at risk (AAR) and area not at risk (non AAR). Expression of Cx43-mRNA and protein was analyzed by qPCR and
Western Blot analysis, respectively. Localization of Cx43 was visualized by confocal immunofluorescence staining.
Results: RIPC reduced the infarct size (I/R: 73 ± 5% vs. RIPC I/R: 34 ± 14%, p < 0.05). Expression of Cx43 mRNA did
not differ between groups. I/R caused a strong decrease of relative Cx43 protein expression in the AAR that was
partly abolished by RIPC. Furthermore, RIPC decreased the level of ischemia-induced dephosphorylation of Cx43.
Confocal immunofluorescence staining showed that I/R caused a loss of the Cx43 signal at the intercalated discs,
while the Cx43 signal at the intercalated discs was partly sustained after RIPC.
Conclusion: Preservation of Cx43 protein expression and phosphorylation after RIPC might protect the rat heart
in vivo.
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In 1993 Przyklenk and colleagues published the observation
that regional mycardial ischemia can protect the remote
myocardial tissue from subsequent ischemia [1]. This
concept – termed remote ischemic preconditioning
(RIPC) – has later been extended by studies showing
that a protective myocardial effect could also be achieved by
short intervals of limb ischemia [2], a fact which makes
RIPC easily applicable and clinically interesting. Recently,
the potential clinical impact of RIPC has been demonstrated
in two studies by Botker et al. [3] and Thielmann et al. [4].* Correspondence: ragnar.huhn@med.uni-duesseldorf.de
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article, unless otherwise stated.Botker and colleagues demonstrated that remote ischemic
conditioning induced by intermittend periods of arm
ischemia before angioplasty increased myocardial salvage
in patients suffering from acute myocardial infarction [3].
The clinical investigation by Thielmann and colleagues
showed that RIPC by transient ischemia of the left upper
arm can provide perioperative myocardial protection and
improve the prognosis of patients undergoing elective
coronary artery bypass surgery [4]. However, the exact
molecular mechanisms underlying RIPC are unknown
and elucidation of these mechanisms is of great clinical
importance. One of the molecules involved in the events
following cardiac ischemic preconditioning (IPC) is Cx43
[5]. Cx43 is the main gap junction component of the heart
ventricle and is mainly located at the intercalated discs. ItCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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chemical coupling of cardiomyocytes [6]. After prolonged
ischemia, Cx43 is dephosphorylated [7] which leads
to the opening of Cx43-formed hemichannels [8] and a
translocation of Cx43 from the gap junctions towards the
plasma membrane [9] or to an intracellular pool [10]. IPC
attenuates this ischemia-induced dephosphorylation of
sarcolemmal Cx43 in rat hearts [11]. Furthermore,
heterozygous deficiency of Cx43 in mice leads to a
loss of the cardioprotection by IPC [12,13].
There is no study showing an impact of RIPC on the
Cx43 phosphorylation status or Cx43 protein distribution
in the context of cardiac I/R. We hypothesised that RIPC
preserves Cx43 phosphorylation and therefore analyzed




Animal experiments were performed in accordance with
the German legislation on protection of animals and the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals (NIH Publication No. 85–23, revised
1996) as described previously [14]. Animals had free access
to food and water at any time. Rats were anesthetized by an
intraperitoneal injection of pentobarbital (100 mg/kg body
weight). Before surgery, adequate depth of anesthesia was
verified by the absence of reaction after pain stimuli. After
tracheal intubation, the right jugular vein was cannulated
for saline and drug infusion, and the left carotid artery was
cannulated for measurement of aortic pressure. A lateral
left-sided thoracotomy was performed and a suture (5–0)
was looped around a major branch of the left coronary
artery. All animals were left untreated for 10 min before the
start of the respective experimental protocol.
Experimental in vivo protocol
Myocardial ischemia and RIPC were performed as described
before. [14]. In brief, rats were randomly assigned to one
of the following groups (Figure 1, n = 6 / group): 1. Sham:
Animals underwent a time matched sham procedureFigure 1 Experimental in vivo protocol. RIPC = remote ischemic precowithout intervention. 2. Remote ischemic preconditioning
only (RIPC): 4 cycles of 5 minutes bilateral hind limb
ischemia/5 minutes reperfusion without I/R. 3. Ischemia/
Reperfuion (I/R): 35 minutes of regional myocardial
ischemia by occlusion of a branch of the left coronary
artery (LAD) followed by 120 minutes of reperfusion. 4.
Remote ischemic preconditioning followed by ischemia/
reperfusion (RIPC + I/R). At the end of the experiment,
the branch of the LAD was re-occluded and 5 ml Evans
blue solution were injected intravenously. By this method,
the area non at risk (non AAR) is stained blue while the
area at risk (AAR) remains unstained. Subsequently, the
hearts were removed, and the myocardium was separated
in AAR and nonAAR. Both tissue fractions were snap
frozen in liquid nitrogen and stored at −80°C until
further analysis.
In a second series, the same experimental protocol
was used to assess infarct size in I/R and RIPC+ I/R animals
(n = 6 / group).
Infarct size measurement
Infarct size measurement was performed as described
previously [15]. In brief, after 120 min of reperfusion, the
hearts were excised with the occluding suture left in place
and then mounted on a modified Langendorff apparatus
for perfusion with ice cold normal saline. After 5 min of
perfusion, the coronary artery was re-occluded and the
heart perfused with 0.2% Evans blue in normal saline for
10 min. Intravascular Evans blue was washed out by
perfusion with normal saline for 10 min. This treatment
identified the area at risk as unstained. The heart was cut
into 2 mm thick transverse slices. The slices were stained
with 0.75% triphenyltetrazolium chloride solution for
15 min at 37°C and fixed in 4% formalin solution for 24 h at
room temperature. The area at risk and the infarcted area
were determined by planimetry using SigmaScan Pro 5®
computer software (SPSS Science Software, Chicago, IL).
RNA isolation
Total RNA of rat hearts was isolated using Trizol reagent
(Invitrogen, Carlsbad, USA) according to the manufacturer’snditioning, I/R ischemia and reperfusion, n = 6 / group.
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tometry (Nanodrop, Thermo Scientific, USA) and RNA
integrity was verified by agarose gel electrophoresis using
2.5 μg of total RNA per lane.
RNA-qPCR assay
1 μg of total RNA was reverse transcribed using the
High Capacity RNA-to-cDNA Master Mix according to
the manufacturer’s protocol (Applied Biosystems). The
qPCR assay for Cx43 was generated by TIB MOLBIOL




reporter probe. GAPDH (Assay ID: Rn_01775763, Applied
Biosystems) was used for normalization. qPCR conditions:
50°C for 2 min, 95°C for 10 min, 40 cycles of 95°C for
15 s, 60°C for 60 s on an Applied Biosystems 7300HT
thermocycler (Applied Biosystems). All samples were
run in triplicates and PCR was repeated twice. Relative
expression was estimated using the ΔΔCq-method [16]
and the relative expression software tool [17].
Subcellular fractionation
The membrane fraction of proteins was obtained by
differential centrifugation. The frozen heart tissue was
pulverized and dissolved in lysis buffer containing
5 mM Tris base, 2 mM EGTA, 50 mM NaF and
2 mM Na3VO4 (as phosphatase inhibitors), a freshly
added protease inhibitor mix (Complete; Roche) and
5 mM DTT. The solution was vigorously homogenized on
ice (Homogenizor; IKA, Staufen, Germany) and then
centrifuged at 600 g at 4°C for 10 min. The supernatant
was centrifuged at 15.000 g at 4°C for 15 minutes,
followed by ultracentrifugation at 100.000 g at 4°C for 1 h.
The pellet was resuspended with lysis buffer containing
1% Triton and incubated on ice for 60 min. The supernatant
containing the membrane fraction was transferred to
a new tube for further analysis.
Western blotting
Protein concentration was measured by the Lowry method
and equal amounts of protein were mixed with loading
buffer (1:1) containing Tris–HCl, glycerol, sodium dodecyl
sulfate and bromphenol blue. Samples were mixed 1:10
with 2-β-mercaptoethanol and incubated at 95°C for
5 min, and loaded on a 10% SDS-polyacrylamide gel. The
proteins were separated by electrophoresis and transferred
onto a polyvinylidene difluoride membrane by tank
blotting (100 V, 1 h). Unspecific binding of the antibody
was blocked by incubation with 5% nonfat dry milk in
Tris-buffered saline containing Tween 20 for 2 h. The
membrane was incubated overnight at 4°C with the
primary antibody (Cx43, ab11370, abcam, Cambridge, UK,1:1000). After washing in fresh, cold Tris-buffered saline
containing Tween, the blot was incubated with the
appropriate horseradish peroxidase conjugated secondary
antibody for 2 h at room temperature. Immunoreactive
bands were visualized by chemiluminescence detected
with a high-resolution camera using an enhanced
chemiluminescence system (Santa Cruz Biotechnology,
Santa Cruz, Calif). The signal intensities of the correspond-
ing bands in Western blot were measured using GelScan
6.0 software (Decon Science Tec, Frankfurt, Germany).
Equal loading of protein was verified by probing the
membrane with Na+/K+-ATPase antibody (Abcam ab 7671,
Cambridge, UK, 1:5000).
Immunofluorescence staining and confocal laser scanning
microscopy
Frozen heart tissue was cut into 8 μm-thick sections,
fixed in 4% paraformaldehyde for 10 min at room
temperature and washed with phosphate buffered
saline. Subsequently, cryosections were blocked and
permeabilized for 1 h with blocking buffer containing
10% normal goat serum and 0.2% saponine in phosphate
buffered saline.
Subsequently, cryosections were incubated with the
primary Cx43 antibody (Abcam ab11370, Cambridge,
UK, 1:1000) at 4°C overnight. A secondary antibody
(Cy3-conjugated goat-anti-rabbit, Jackson Immuno
Research Laboratories, USA, Code 111-165-144, 1:400)
was applied for 4 h at room temperature. Glass slides were
washed with phosphate buffered saline and mounted to
coverslips with mounting medium (ProLong Gold antifade
reagent with DAPI; Invitrogen). Immunostained samples
were analyzed using a Zeiss LSM510META confocal
microscope.
Statistical analyis
All values were tested for normal distribution and are
expressed as mean ± SD. Hemodynamic data were
analyzed by two-way analysis of variance (ANOVA)
followed by Tukey’s post hoc test (Sigmastat Software,
version 3.5). After failing testing for normal distribution, a
Kruskal-Wallis test followed by Dunn’s posthoc testing
was performed for analyzing Western Blot data of Cx43




No significant differences in hemodynamic baseline vari-
ables were observed between treatment groups. Heart rate
was significantly lower in the I/R and the RIPC + I/R
group after 120 minutes of reperfusion compared to
baseline values and to Sham animals. Blood pressure
was significantly lower in I/R and RIPC + I/R animals
Figure 3 Relative Cx43 mRNA expression measured by qPCR.
There is no differential mRNA expression between the groups
(Data are mean ± SD, n = 6 / group).
Figure 2 RIPC leads to a significant decrease of the infarct size
after I/R in percentage of the area at risk. RIPC = remote ischemic
preconditioning, I/R ischemia and reperfusion (Data are mean ± SD,
n = 6 / group. * p < 0.05). Representative pictures of TTC-stained
hearts from I/R and RIPC-I/R animals are shown (white: infarct area,
red: AAR, blue: area not at risk, not perfused by LAD).
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values and was lower in the I/R group compared to Sham
animals (details in Additional file 1: Table S1 and S2).
Infarct size measurement
In the I/R group, infarct size was 72.6 (±5) % (Figure 2).
Infarct size was reduced by RIPC to 34.1 (±14) % (p < 0.01,
n = 6). Furthermore, there was no difference in the
area at risk between groups (data not shown), therefore the
differences in infarct sizes were not caused by differences
in area at risk.
Cx43 mRNA expression
Realtime quantitative PCR was performed to analyze
the expression of Cx43 mRNA. There were no differences
in the expression level of Cx43 mRNA between the
groups (Figure 3).
Cx43 protein expression
Cx43 protein expression was analyzed by Western
Blotting using the membrane fractions of heart tissue. A
Cx43 antibody detecting both phosphorylated as well as
unphosphorylated Cx43 was applied.
Total Cx43 protein expression was significantly reduced
in the AAR of hearts subjected to I/R hearts compared to
Sham hearts (relative expression versus Na+/K+-ATPase:
0.73 for I/R vs. 2.65 for Sham, p < 0.05) (Figure 4b).
Interestingly, this decrease is not only observed in
the AAR but also in the non AAR of I/R hearts
(relative expression 1.05 versus Na+/K+-ATPase, p < 0.05).
In contrast, there is no significant decrease in Cx43
protein expression in the AAR of hearts pretreated
with RIPC (RIPC + I/R, relative expression 1.43).
Cx43 can be phosphorylated at several sites including
Ser365, Ser325, Ser328 and Ser330 and phosphorylation of
these sites is known to affect SDS/PAGE migration [18].
The fastest migrating band is termed P0, it is the
dephosphorylated form of Cx43. For analyzing the
phosphorylation status of Cx43, we determined the
ratio of phosphorylated to total Cx43 protein content.
Phosphorylation of Cx43 was significantly decreased in
the AAR of I/R hearts (Phosphorylated Cx43/total
Cx43 = 0.22) in comparison to Sham (0.71) as well as
in comparison to the AAR of RIPC + I/R hearts (0.59)
(Figure 4c). Thus, RIPC prevents the I/R-induced
dephosphorylation of Cx43.
Immunofluorescence staining of Cx43
To analyze the distribution of Cx43, heart tissue was la-
belled with a Cx43 antibody. In Sham animals, the
strongest Cx43 signal was detected at the interca-
lated discs (Figure 5A). In contrast, in the AAR of I/R
sections the Cx43 signal at the intercalated discs was
lost and Cx43 could to a lesser degree be detectedin the cardiomyocyte plasma membrane (Figure 5B).
In the AAR of heart sections treated with RIPC
before I/R, some of the Cx43 protein content at the
intercalated discs was preserved and to a lesser amount
lateralized to the plasma membrane (Figure 5C).
Figure 4 Western Blot analysis of Cx43 protein expression. (A) Exemplary original blot showing the expression of Cx43 and Na+/K+-ATPase.
The upper Cx43 band represents the expression of phosphorylated Cx43, while the lower band corresponds to dephosphorylated Cx43. (B) Relative
expression of total Cx43 protein vs. Na+/K+-ATPase. Cx43 expression is significantly lower in the AAR of I/R hearts compared to Sham. (C) Analysis of
phosphorylated vs. dephosphorylated Cx43. The degree of dephosphorylated Cx43 is higher in the AAR of I/R hearts compared to Sham and RIPC + I/R
hearts. RIPC = remote ischemic preconditioning, I/R = ischemia and reperfusion, (Data are median, min to max, n = 6 / group. * p < 0.05).
Brandenburger et al. Journal of Translational Medicine 2014, 12:228 Page 5 of 7
http://www.translational-medicine.com/content/12/1/228Discussion
In this study we show that RIPC 1) attenuates the
ischemia-induced dephosphorylation of Cx43, 2) partially
prevents the lateralization of Cx43 from the intercalated
discs to the plasma membrane, and 3) reduces the degree
of Cx43 degradation.
Though being first described 20 years ago [1], the exact
molecular mechanisms underlying RIPC are unknown.
Humoral factors, a neural pathways or microRNAs [19]
have been proposed for mediating the cardioprotective
effects following RIPC (reviewed in [20]). The molecular
events following IPC, where myocardial I/R is induced by
direct transient ligation of a coronary artery, are betterFigure 5 Immunofluorescence staining of Cx43 in rat hearts. (A) Cx43
hearts, the Cx43 signal at the intercalated discs is lost and Cx43 is partly lat
preservation of Cx43 at the intercalated discs after I/R. RIPC = remote ischemcharacterized than the mechanisms underlying RIPC,
where the ischemic event occurs in an organ distinct from
the heart. While some studies suggest that the molecular
events mediating RIPC are similar to events following IPC
[21], a study of our group has shown that RIPC exhibits a
different signalling pattern compared to IPC [14]. One
protein that has been extensively studied in the context of
IPC is Cx43. Cx43 is an integral membrane protein
that is mainly localized at the sarcolemma of ventricular
cardiomyocytes where six connexin molecules assemble
into a connexon or hemichannel [22]. The protein
can be phosphorylated at numerous Serin sites including
Ser325, Ser328, Ser330, Ser365 and Ser262. Phosphorylationis mainly located at the intercalated discs of Sham hearts. (B) In I/R
eralized to the plasma membrane. (C) RIPC leads to a partial
ic preconditioning, I/R = ischemia and reperfusion.
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conformational changes within the Cx43 molecule
[23] and the phosphorylation status of Cx43 is related
to stress response and resistance of cells to injury [24].
Cx43 is a target protein of several protein kinases such as
protein kinase A (PKA), protein kinase C (PKC), protein
kinase G (PKG), protein tyrosine kinases and mitogen
activated protein kinases (MAP kinases) [7].
Myocardial ischemia, Cx43 and cardioprotection
It has been shown that prolonged myocardial ischemia
leads to a dephosphorylation of Cx43 [25]. Our data
confirm this finding. In addition, myocardial ische-
mia causes a re-distribution of Cx43 to the lateral
plasma membrane. Besides this lateralization, some
of the Cx43 is degraded following prolonged cardiac
ischemia [26].
In our experimental model, we could reproduce both
findings, lateralization and degradation of Cx43 caused
by myocardial I/R. These effects of myocardial I/R on
Cx43 dephosphorylation, lateralization and degradation
can be modulated by cardioprotective interventions
including IPC. Ischemia-induced dephosphorylation of
sarcolemmal Cx43 is attenuated by IPC in rat hearts
[11], which may be related to an enhanced association of
Cx43 with kinases such as PKC and p38 mitogen-activated
protein kinases [27]. Furthermore, heterozygous deficiency
of Cx43 in mice leads to a loss of cardioprotection by IPC
[12,13]. There are no data dealing with the role of Cx43 in
RIPC. We therefore analyzed a possible impact of RIPC on
both Cx43 mRNA and protein expression levels and
cellular distribution in the context of cardiac I/R in
male Wistar rats. Our data demonstrate that RIPC
protects against the I/R-induced dephosphorylation of
Cx43. RIPC also attenuates the I/R-induced degrad-
ation and lateralization of Cx43. Dephosphorylation of
Cx43 increases the permeability of gap junctions and
thereby contributes to the propagation of I/R injury
[28], as during reperfusion following prolonged ischemia a
death factor (such as sodium ions) is able of spreading
more easily between cells [29]. An uncoupling of this
propagation as a consequence of a preservation of
phosphorylation is potentially cardioprotective. Therefore,
presevation of Cx43 phosphorylation and protein content
as shown in our study could contribute to the protective
effects of RIPC. We furthermore show that the preservation
of Cx43 protein is not associated with changes in Cx43
mRNA expression. This is in line with other studies
showing that changes in Cx43 protein content and
phosphorylation following hypoxia are not accompanied
by changes in Cx43 mRNA expression [30].
In IPC, the preserved phosphorylation of Cx43 is related
to an enhanced association of Cx43 with kinases such as
PKC and p38 mitogen-activated protein kinases (MAPK)[27], while it is independent on the RISK and SAFE
pathway [31]. We could show previously that the
PKC-MAPK pathway is most likely not involved in
the protective effects of RIPC [14]. It therefore remains to
be elucidated how RIPC contributes to the preservation of
Cx43 phosphorylation on a molecular level.
While most Cx43 molecules are found in the
sarcomlemma of cells, Cx43 is also located in the
mitochondrial membrane of mammalian cardiomyocytes
[32,33]. It has been shown that mitochondrial Cx43 is
involved in the events following IPC [32], but there
are no data dealing with mitochondrial Cx43 in the
context of RIPC. Our study however focused on
sarcolemmal Cx43 and further studies are necessary
to analyze a potential influence of mitochondrial Cx43 in
the context of RIPC.
Conclusion
In summary, our data show that RIPC has an impact on
ischemia-induced Cx43 dephosphorylation, lateralization
and degradation. Further studies are necessary to investigate
the exact molecular events leading to the preserved
phosphorylation of Cx43 following RIPC and a potential
impact of mitochondrial Cx43.
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